Moderna Stock Faces New Valuation Test After Cancer Vaccine Rally Draws Rare Sell Rating
Moderna's historic cancer-vaccine breakthrough has transformed the investment case around the biotech company, but one Wall Street firm now says investors have pushed the stock too far ahead of the evidence. Rothschild & Co…